Home
Apellis

Apellis Market Share Analysis for November 2025

Dr. Deschatelets' 3 decades of drug development experience includes co-founding Apellis, Potentia Pharmaceuticals, and Syntetica Fine Chemicals. Dr. Deschatelets has extensive experience in nanobiotechnology and in the synthesis of organic molecules and bioconjugates.

Health > Biotechnology and Pharmaceuticals

Domainapellis.com

Year Founded2009

Employees501 - 1000

Annual Revenue$500M - $1B

Apellis

Apellis (including company regionals)

apellis.com

See more website traffic and engagement information

Apellis Revenue up to November 2025 is 500M - 1B

revenue generated by Apellis top domains

Apellis top domains revenue over 3 years

Revenue for Apellis top domains

apellis.com500M - 1B

See more with Sales Intelligence

Total visits to Apellis's top domains

Understand Apellis market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

apellis.com27.9K

See more with Sales Intelligence

Avg. visit duration in Apellis's top domains

Analyze Apellis engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

apellis.com00:01:25

See more with Sales Intelligence

Avg. pageviews on Apellis's top domains

See how Apellis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

apellis.com2.06

See more with Sales Intelligence

Apellis top competitors by domain

Top similar sites in November 2025, ranked by their affinity

neec.comCompany NameNew England Eye CenterEmployees201 - 500HQUnited States, Massachusetts, BostonAnnual revenue$25M - $50MTotal visits9.7KHealth > Medicine

Top technologies used by Apellis

These are the website technologies, by industry, used by Apellis top domains

Email Services (5)

Sendgrid

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

Marketing (3)

Google Marketing Platform

More Technologies

10

See all

News & Signals from Apellis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsApellis Pharmaceuticals inc. hires Meltzer.Dr. Meltzer joins Apellis as a seasoned biopharma executive with demonstrated success in advancing innovative therapies from early discovery stages through regulatory milestone achievements and market introduction.

NewsApellis Pharmaceuticals inc. hires Craig Wheeler as Board of Directors.Apellis announces Craig Wheeler to join the Board of Directors.

NewsMarsh leaves Apellis Pharmaceuticals inc. as Vice President, North America Sales and Marketing in Ophthalmology.Ms. Marsh joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President, North America Sales and Marketing in Ophthalmology, leading the commercial US launch for Syfovre, the first approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration.